US Patent 8,383,678: Scope, Claims, Expiration, Orange Book Status, and Generic Risk

US Patent 8,383,678 protects a specific omega-3 free-fatty-acid softgel architecture associated with Epanova, including a high-concentration eicosapentaenoic acid (EPA) composition, porcine Type A gelatin, accelerated-storage disintegration performance, optional docosahexaenoic acid (DHA), and certain coatings. The patent is materially narrower than a general omega-3 composition patent because infringement requires the claimed free-acid formulation and capsule characteristics.

The patent issued February 26, 2013, from an application claiming priority to April 25, 2008. Its ordinary 20-year patent term runs to April 25, 2029, subject to any patent-term adjustment, terminal disclaimer, or applicable regulatory extension reflected in official records. The claims do not cover all EPA products, all omega-3 capsules, or ethyl ester products such as Lovaza or Vascepa.

What does US Patent 8,383,678 protect?

The patent claims a pharmaceutical product and a treatment method built around four technical elements:

A soft gelatin capsule.
A composition containing at least about 50 wt% EPA in free-acid form.
Porcine Type A gelatin with a specified disintegration profile after storage at 40°C.
Treatment of hypertriglyceridemia using the claimed capsule.

The claimed EPA is 5,8,11,14,17-eicosapentaenoic acid. The claims require the free fatty acid, not an ethyl ester, triglyceride, phospholipid, or another esterified form.

The independent product claims are claims 1 and 4. Claim 1 is defined partly by performance. Claim 4 is defined by the gelatin composition. Claim 13 is the independent method-of-treatment claim.

Claim group	Principal limitation	Commercial significance
Claims 1-3	At least 50 wt% EPA free acid; porcine Type A gelatin; disintegration within 30 minutes after 3, 6, or 12 months at 40°C	Protects capsule stability and performance
Claim 4	At least 50 wt% EPA free acid; gelatin consists essentially of porcine Type A gelatin	Protects a narrower gelatin formulation
Claims 5 and 7	EPA at about 50-60 wt%, with DHA at about 20-30 wt%	Tracks an EPA/DHA free-acid blend
Claim 6	At least 50 wt% EPA and DHA at about 20-30 wt%	Covers the broader EPA/DHA range
Claims 8-10	100-2,000 mg composition per capsule; preferred 500 mg or 1,000 mg	Covers practical dose-unit configurations
Claims 11-12	Neutral polyacrylate coating, including poly(ethyl acrylate-methyl methacrylate)	Adds a coating-dependent formulation layer
Claims 13-20	Hypertriglyceridemia treatment using the claimed capsule	Creates method-of-use exposure for qualifying products

How do the independent claims define infringement risk?

Claim 1: product claim with a functional disintegration limitation

Claim 1 requires all of the following:

A soft gelatin capsule.
A pharmaceutical composition inside the capsule.
At least about 50 wt% EPA in free-acid form.
Sufficient porcine Type A gelatin.
Disintegration within 30 minutes in purified water at 37°C.
The performance must remain after at least three months of storage at 40°C.

The storage condition is important. A capsule that disintegrates rapidly when newly manufactured but fails after accelerated aging may fall outside the literal scope of claim 1. Conversely, the claim is not limited to a particular manufacturing process, capsule shape, fill weight, excipient, or commercial brand.

Claims 2 and 3 extend the same performance requirement to six-month and 12-month accelerated-storage periods. They are narrower than claim 1 because they impose longer storage-performance requirements.

Claim 4: composition-defined gelatin claim

Claim 4 requires that the gelatin consist essentially of porcine Type A gelatin. This is narrower than a claim directed generally to soft gelatin capsules but may be easier to evaluate analytically than claim 1 because it does not expressly require the three-, six-, or 12-month disintegration test.

The phrase "consists essentially of" generally permits components that do not materially affect the basic and novel characteristics of the claimed capsule. The scope depends on the patent specification, prosecution history, and the technical effect attributed to the gelatin composition.

Claim 13: method-of-treatment claim

Claim 13 covers administering an effective number of the claimed capsules to a patient with hypertriglyceridemia. A competing product must satisfy both the formulation limitations and the treatment-use limitations for literal infringement.

The method claims do not cover treatment of every lipid disorder. They specifically recite hypertriglyceridemia. Claims 19 and 20 further require daily administration of multiple capsules, with each capsule containing 100-2,000 mg of the composition.

What formulations are protected by US 8,383,678?

The central formulation is an EPA-rich free-fatty-acid mixture in a softgel capsule. Claims 5-7 identify the principal preferred composition:

EPA free acid: approximately 50-60 wt%.
DHA free acid: approximately 20-30 wt%.
Remaining material: other omega-3 fatty acids, excipients, stabilizers, or formulation components, subject to the claim construction and specification.

The claims do not require DHA in every embodiment. Claims 1, 2, 3, 4, 8-14, and 17-20 can apply without the DHA limitation unless the relevant dependent claim is asserted.

The patent also covers capsules containing:

100 mg to 2,000 mg of the pharmaceutical composition;
approximately 500 mg; or
approximately 1,000 mg.

The neutral polyacrylate coating is optional. Claims 11, 12, 17, and 18 cover capsules with that additional coating, including poly(ethyl acrylate-methyl methacrylate).

How does the patent distinguish EPA free acid from Vascepa and Lovaza?

The chemical form is the primary distinction.

Product	Principal omega-3 form	Relevance to US 8,383,678
Epanova	Omega-3 carboxylic acids, including EPA and DHA free acids	Closest commercial product profile
Vascepa	Icosapent ethyl, an EPA ethyl ester	Generally outside the literal free-acid limitation
Lovaza	Omega-3-acid ethyl esters, including EPA and DHA ethyl esters	Generally outside the literal free-acid limitation
Generic omega-3 fish oil	Varies, commonly triglycerides or ethyl esters	Requires chemical-formulation analysis

A product containing EPA ethyl ester does not ordinarily satisfy a claim requiring EPA "in free acid form." A patent holder could pursue a doctrine-of-equivalents theory in an appropriate case, but the chemical-form limitation creates a substantial barrier to such an argument, particularly where the patent distinguishes free acids from esterified products.

What is the FDA and Orange Book status of the patent?

Epanova was approved by the FDA in 2014 for use with diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. The product contained omega-3 carboxylic acids rather than the ethyl ester chemistry used in Lovaza and Vascepa. The FDA approved Epanova under NDA 205787.[1]

US 8,383,678 is associated with the Epanova patent estate and has been identified in FDA patent-listing materials for the product. Orange Book relevance depends on the specific NDA listing and the FDA edition being reviewed. An Orange Book listing does not establish that every claim in the patent covers every product version. It identifies a patent asserted by the NDA holder as relevant to the approved drug.

Regulatory item	Status
Product associated with the patent	Epanova
Active ingredient category	Omega-3 carboxylic acids, including EPA and DHA free acids
FDA application	NDA 205787
Initial FDA approval	2014
Patent issue date	February 26, 2013
Earliest stated priority date	April 25, 2008
Ordinary patent-term endpoint	April 25, 2029, before any applicable adjustment
Regulatory pathway for a challenger	ANDA or, depending on the proposed product and labeling, 505(b)(2)

The commercial discontinuation or limited availability of a branded product does not, by itself, cancel an unexpired patent. A challenger must evaluate patent status, Orange Book listing status, FDA approval status, and any statutory exclusivity separately.

When does US 8,383,678 lose exclusivity?

The ordinary patent term is expected to end in 2029 based on the April 25, 2008 priority date. The relevant date for a precise freedom-to-operate opinion is the expiration date recorded for the issued patent after accounting for:

Patent-term adjustment.
Any terminal disclaimer.
Patent-term extension under 35 U.S.C. § 156.
Correct priority-claim analysis.
Continuation or divisional prosecution history.

The patent is not a biologic patent and does not create biosimilar exclusivity. Its principal exclusivity effect is against an ANDA or 505(b)(2) product that uses the same EPA free-acid capsule architecture and falls within one or more unexpired claims.

What Paragraph IV risks exist for a generic competitor?

A generic or follow-on developer would likely assess a Paragraph IV certification if US 8,383,678 is listed in the Orange Book for the relevant reference product and remains unexpired.

The strongest noninfringement positions would involve:

EPA supplied as an ethyl ester rather than free acid.
EPA concentration below about 50 wt%.
A non-porcine gelatin shell.
Gelatin that is not Type A.
Failure to meet the claimed accelerated-storage disintegration limitation.
A capsule outside the claimed composition or dosage ranges.
A product not labeled for treatment of hypertriglyceridemia, where method claims are relevant.

The strongest validity challenges would likely focus on:

Anticipation by earlier omega-3 free-acid softgel disclosures.
Obviousness based on known EPA/DHA free-acid formulations, gelatin systems, and disintegration testing.
Written-description or enablement issues concerning the breadth of the functional limitation.
Indefiniteness arguments involving terms such as "sufficient," "about," and "consists essentially of."

The functional disintegration limitation may provide meaningful distinguishing value over prior art, but it can also create evidentiary issues. The patent holder would need reliable testing under the claimed storage and disintegration conditions. The challenger would likely seek production records, stability data, capsule-shell specifications, and batch testing.

How strong is the patent estate?

US 8,383,678 has moderate strength against a product that intentionally copies the Epanova-type formulation. Its practical strength is lower against chemically different omega-3 products.

Risk factor	Assessment
Product-specific formulation coverage	Strong against EPA/DHA free-acid softgels matching the claimed ranges
Coverage of ethyl ester products	Weak
Coverage of non-porcine gelatin	Weak under claims requiring porcine Type A gelatin
Coverage of general omega-3 products	Limited
Manufacturing-process coverage	Limited; the claims focus on product characteristics
Method-of-use coverage	Relevant to hypertriglyceridemia labeling and use
Testing burden	Significant because of accelerated-storage disintegration requirements
Biosimilar relevance	None; this is a small-molecule drug product
Generic design-around potential	Meaningful through chemical form, shell material, or composition changes

The patent is more valuable as a formulation barrier than as a broad active-ingredient patent. A competitor that retains EPA free acid but changes the capsule shell, EPA concentration, DHA content, or performance profile may avoid particular claims, although the full patent family and other formulation patents must be reviewed before relying on a design-around.

What patent litigation and settlements affect US 8,383,678?

No litigation or settlement can be attributed to this patent from the claim text alone. The relevant litigation screen should distinguish:

Patent cases involving Epanova or Omthera/AstraZeneca.
ANDA Paragraph IV cases naming US 8,383,678.
Cases involving other omega-3 products, especially Vascepa and Lovaza.
Patent disputes concerning EPA free acid versus EPA ethyl ester.
Declaratory-judgment actions concerning Orange Book listings.

Vascepa litigation is not automatically relevant because Vascepa uses icosapent ethyl, while US 8,383,678 requires EPA free acid. Likewise, litigation involving Lovaza generally concerns omega-3-acid ethyl esters and cannot be transferred directly to the free-acid claims.

What licensing and commercial issues matter?

The patent was developed within the Omthera/Epanova commercial platform and became relevant to AstraZeneca after its acquisition of Omthera. Its commercial value depended on an approved and marketed EPA/DHA free-acid product. It does not provide a general license to use EPA, DHA, fish oil, or omega-3 formulations.

A transaction involving this patent should address:

Ownership and chain of title.
Patent-family members in the United States and other jurisdictions.
Orange Book listing history.
Any license, assignment, or collaboration agreement involving Omthera and AstraZeneca.
Epanova NDA status and commercial rights.
Stability and disintegration data supporting claim enforcement.
Patent-term adjustment and any regulatory extension.
Pending continuation applications or related formulation patents.

How does geographic coverage differ outside the United States?

US 8,383,678 has no automatic effect outside the United States. Foreign protection depends on national-stage applications and granted family members in jurisdictions such as Europe, Canada, Japan, and Australia. Each country requires separate review of:

Grant status.
Local expiration date.
Validity proceedings.
Supplementary protection certificate eligibility.
Claim amendments during prosecution.
National definitions of free acid, gelatin, and functional performance.

A US design-around does not establish freedom to operate in Europe or other markets. The accelerated-storage and capsule-composition claims may also have been narrowed differently in foreign prosecution.

Key Takeaways

US 8,383,678 primarily protects an Epanova-type softgel containing at least about 50 wt% EPA in free-acid form.
The patent requires specific capsule characteristics, including porcine Type A gelatin and, for several claims, accelerated-storage disintegration within 30 minutes.
Claims 1 and 4 are the principal product claims; claim 13 is the principal treatment claim.
DHA is required only for selected dependent claims, not for the entire patent.
Vascepa and Lovaza are materially different because they use ethyl ester omega-3 chemistry.
The ordinary patent term runs to approximately April 25, 2029, subject to official term adjustments.
Generic exposure is highest for an EPA/DHA free-acid softgel that copies the claimed gelatin and performance profile.
The patent does not create biosimilar exclusivity and does not broadly cover all omega-3 products.
Design-around opportunities include changing chemical form, shell material, composition, or disintegration performance.
Orange Book, FDA, USPTO, and complete patent-family records must be read together for a final launch or litigation position.

FAQs

Does US 8,383,678 cover pure EPA products?

Potentially, if the product contains at least about 50 wt% EPA in free-acid form and satisfies the applicable capsule limitations. DHA is not required by every claim.

Does a fish-oil softgel infringe US 8,383,678?

Not automatically. The product would need to satisfy the claimed EPA free-acid concentration, capsule shell, and, for relevant claims, accelerated-storage disintegration requirements.

Can an ANDA applicant avoid the patent by using gelatin from a different animal?

A non-porcine shell may avoid claims expressly requiring porcine Type A gelatin, although the full patent family and any other formulation patents must still be assessed.

Is Epanova protected by biologic exclusivity?

No. Epanova is a small-molecule omega-3 pharmaceutical product. Biosimilar exclusivity does not apply.

Does patent expiration eliminate all generic launch barriers?

No. Launch timing may also depend on other unexpired patents, Orange Book listings, regulatory exclusivity, certification strategy, litigation, labeling, and FDA approval requirements.

References

U.S. Food and Drug Administration. (2014). Epanova (omega-3-carboxylic acids) prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,383,678, Pharmaceutical compositions comprising omega-3 fatty acids.
U.S. Code, Title 35, §§ 156, 271, and 282.
AstraZeneca. (2014). Epanova FDA approval materials and product information.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0403247	Feb 13, 2004

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	047799	⤷ Start Trial
Austria	E457720	⤷ Start Trial
Australia	2005215198	⤷ Start Trial
Brazil	PI0507473	⤷ Start Trial
Canada	2555064	⤷ Start Trial
China	107690770	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,383,678

Summary for Patent: 8,383,678